Cargando…

Targeted Therapy in Ovarian Cancer

Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmott, Lyndsay J., Fruehauf, John P.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814233/
https://www.ncbi.nlm.nih.gov/pubmed/20130818
http://dx.doi.org/10.1155/2010/740472
_version_ 1782176988645031936
author Willmott, Lyndsay J.
Fruehauf, John P.
author_facet Willmott, Lyndsay J.
Fruehauf, John P.
author_sort Willmott, Lyndsay J.
collection PubMed
description Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherapy. Unfortunately, many patients will recur and ultimately die from their disease. Targeted therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Angiogenesis inhibitors have shown success in many tumor types and have also demonstrated promise in trials involving patients with ovarian cancer. PARP inhibitors may be potentially active agents in patients with BRCA-associated ovarian cancer. Trials that have evaluated combinations of targeted agents have often revealed untoward toxicities, thus tempering enthusiasm for this approach.
format Text
id pubmed-2814233
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28142332010-02-03 Targeted Therapy in Ovarian Cancer Willmott, Lyndsay J. Fruehauf, John P. J Oncol Review Article Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherapy. Unfortunately, many patients will recur and ultimately die from their disease. Targeted therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Angiogenesis inhibitors have shown success in many tumor types and have also demonstrated promise in trials involving patients with ovarian cancer. PARP inhibitors may be potentially active agents in patients with BRCA-associated ovarian cancer. Trials that have evaluated combinations of targeted agents have often revealed untoward toxicities, thus tempering enthusiasm for this approach. Hindawi Publishing Corporation 2010 2010-01-14 /pmc/articles/PMC2814233/ /pubmed/20130818 http://dx.doi.org/10.1155/2010/740472 Text en Copyright © 2010 L. J. Willmott and J. P. Fruehauf. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Willmott, Lyndsay J.
Fruehauf, John P.
Targeted Therapy in Ovarian Cancer
title Targeted Therapy in Ovarian Cancer
title_full Targeted Therapy in Ovarian Cancer
title_fullStr Targeted Therapy in Ovarian Cancer
title_full_unstemmed Targeted Therapy in Ovarian Cancer
title_short Targeted Therapy in Ovarian Cancer
title_sort targeted therapy in ovarian cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814233/
https://www.ncbi.nlm.nih.gov/pubmed/20130818
http://dx.doi.org/10.1155/2010/740472
work_keys_str_mv AT willmottlyndsayj targetedtherapyinovariancancer
AT fruehaufjohnp targetedtherapyinovariancancer